European Medicines Agency (EMA) receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2

Assessment of BNT162b2, a COVID‑19 mRNA vaccine developed by BioNTech and Pfizer, will proceed under an accelerated timeline; and an opinion on the marketing authorisation could be issued within weeks, depending on quality, safety and effectiveness data.

Source:

European Medicines Agency